Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...

QuickShot Nav Delivers Versatile Map-and-Ablate Performance in the Quick AF Trial CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, announc ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, announced the continuation of the Quick AF study, which evaluates the investigational ...

One of AI’s most immediate impacts is in screening and identifying patients who may have asymptomatic or paroxysmal AF, those ...

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

Aurobindo Pharma jumped 3.42% to Rs 1,119.55 after the pharma company said that it has received final approval from US Food and Drug Administration (USFDA) to manufacture and market Rivaroxaban ...